Thursday, 21 January 2021
EU Graphene Flagship highlights the ICN2 spin-off INBRAIN Neuroelectronics
The news explains that INBRAIN is currently working to ensure patient safety and to comply with necessary preclinical regulatory milestones. The company plans to start its first in-human studies in 2021.
INBRAIN Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, was established with the mission to develop brain-implants based on graphene technology for application in patients with epilepsy, Parkinson’s, and other neuronal diseases. These smart devices, built around an innovative graphene electrode, will decode with high fidelity neural signals from the brain and produce a therapeutic response adapted to the clinical condition of the specific patient.
The Graphene Flagship, one of Europe's biggest ever research initiative, has highlighted this spin-off on its website. According to the text, INBRAIN is currently working to ensure patient safety and to comply with necessary preclinical work and clinical regulatory milestones. The company plans to start its first in-human studies in 2021.
Read more in the Graphene Flagship website.